Genocea Biosciences Inc: Shares boosted by positive data from cancer trial

Genocea Biosciences

03/06/2019 13:11

** Shares of cancer immunotherapy developer  GNCA.O  jump
25.7% to $7.05 premarket 
    ** Co announces promising data from its ongoing trial of
GEN-009, its lead cancer treatment vaccine, at the 2019 Annual
Meeting of the American Society of Clinical Oncology (ASCO)
 urn:newsml:reuters.com:*:nGNX8K3dXq  
    ** Says in five patients, GEN-009 monotherapy elicited T
cell responses to 91%; the treatment has been well tolerated to
date, with no dose-limiting toxicities 
    ** GEN-009 abstract was chosen as a Top 10 Immunooncology
abstract by the Journal of Clinical Oncology (JCO) as part of
the ASCO conference - H.C. Wainwright & Co 
    ** H.C. Wainwright raises PT of GNCA to $42 from $5.75 -
believes an important inflection point has been reached
    ** GNCA shares among top percentage gainers across U.S.
exchanges in trading before the bell 
    ** Up to Friday's close, GNCA shares had more than doubled
in value this year 

 (Reporting by Shreyashi Sanyal in Bengaluru)
 ((RM: Shreyashi.Sanyal.thomsonreuters.com@reuters.net))